1.
ACS Cent Sci
; 9(5): 849-857, 2023 May 24.
Artículo
en Inglés
| MEDLINE
| ID: mdl-37252346
RESUMEN
The advancement of nirmatrelvir, the active ingredient in Paxlovid, from discovery to emergency use authorization was achieved in just 17 months, requiring an unprecedented rate of chemical process development.
